Search

Background: Flurbiprofen 8.75 mg lozenges and oromucosal sprays are used for symptomatic relief of sore throat in patients aged 12 years and over. The documented adverse events of flurbiprofen use include those related to its pharmacological actions, namely, increased risk of haemorrhagic events, however other adverse events (such as nephrotoxicity and cardiac failure) have been known to occur. The likelihood of occurrence of adverse events increases when flurbiprofen is used concomitantly with some other medications. Therefore, the objective of this systematic review was to collate the current evidence on adverse events which occur with flurbiprofen 8.75 mg dose (any formulation), in particular as a result of interaction with other medicinal products, with a focus on non-haemorrhagic events. Methods: Systematic searches of the literature were conducted to identify literature on any formulation of flurbiprofen 8.75 mg up to the date of the electronic database search (data lock: 28 April 2020). Publications were screened to identify studies reporting non-haemorrhagic adverse events with flurbiprofen 8.75 mg and/or non-haemorrhagic adverse events in the comparator arm. Data extraction was performed for eligible studies according to pre-defined criteria and summarised in narratives, tables and figures. Risk of bias and certainty of evidence assessments were planned for each included study where results relating to the primary objective of the systematic review were available. Results: Of 1,528 publications identified by systematic literature searches, 26 met the inclusion criteria and were included in this review. None of these 26 studies contained information on non-haemorrhagic adverse events occurring as a result of a drug-drug interaction (interaction with concomitant medication used with flurbiprofen 8.75 mg), as per the primary objective and secondary objectives of the systematic review. Conclusion: Results from this systematic review on the risk of non-haemorrhagic events did not provide evidence for these events occurring as a result of interaction with other medicinal products. Additional appropriately designed studies would be required to confirm whether these findings suggest a true absence of risk or limitations in reporting. [ABSTRACT FROM AUTHOR]

In all pivotal trials of COVID-19 vaccines, the history of previous SARS-CoV-2 infection was mentioned as one of the main exclusion criteria. In the absence of clinical trials, observational studies are the primary source for evidence generation. This study aims to describe the patient-reported adverse drug reactions (ADRs) following the first COVID-19 vaccination cycle, as well as the administration of booster doses of different vaccine brands, in people with prior SARS-CoV-2 infection, as compared to prior infection-free matched cohorts of vaccinees. A web-based prospective study was conducted collecting vaccinee-reported outcomes through electronic questionnaires from eleven European countries in the period February 2021–February 2023. A baseline questionnaire and up to six follow-up questionnaires collected data on the vaccinee's characteristics, as well as solicited and unsolicited adverse reactions. Overall, 3886 and 902 vaccinees with prior SARS-CoV-2 infection and having received the first dose or a booster dose, respectively, were included in the analysis. After the first dose or booster dose, vaccinees with prior SARS-CoV-2 infection reported at least one ADR at a higher frequency than those matched without prior infection (3470 [89.6%] vs. 2916 [75.3%], and 614 [68.2%] vs. 546 [60.6%], respectively). On the contrary side, after the second dose, vaccinees with a history of SARS-CoV-2 infection reported at least one ADR at a lower frequency, compared to matched controls (1443 [85.0%] vs. 1543 [90.9%]). The median time to onset and the median time to recovery were similar across all doses and cohorts. The frequency of adverse reactions was higher in individuals with prior SARS-CoV-2 infection who received Vaxzevria as the first dose and Spikevax as the second and booster doses. The frequency of serious ADRs was low for all doses and cohorts. Data from this large-scale prospective study of COVID-19 vaccinees could be used to inform people as to the likelihood of adverse effects based on their history of SARS-CoV-2 infection, age, sex, and the type of vaccine administered. In line with pivotal trials, the safety profile of COVID-19 vaccines was also confirmed in people with prior SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]

This research paper represents the estimation and reduction of eddy current loss in a Magnetic Fault Current Limiter (MFCL). The nonlinear model of the device is established using electromagnetic coupled circuit supported by Finite Element Model. The current limiting performance of the MFCL is investigated by simulation study as well as laboratory testing. It is further observed that a significant amount of eddy current loss takes place inside the core and permanent magnet of the device. Different methods (shorting ring, lamination of permanent magnet and variation of magnet length) are proposed to reduce the eddy current. The advantages and disadvantages of these methods are discussed. Some design modifications are also proposed to minimize the temperature rise caused by the eddy current. [ABSTRACT FROM AUTHOR]

The Cardiological Society of India (CSI) celebrated its 75th anniversary with its Annual Conference in Kolkata in December 2023. The conference included a Global Summit that brought together experts from international cardiac societies to discuss topics such as artificial intelligence in cardiometabolic disease prevention and air pollution mitigation. The conference also highlighted the emerging epidemic of heart failure and featured presentations on various aspects of cardiology, including hypertension, hyperlipidemia, and imaging. The conference also addressed the importance of women's cardiac health and included sessions on heart disease in women and cardio-obstetrics. Additionally, there was a focus on artificial intelligence and digital cardiology, as well as the presentation of position statements on dyslipidemia management, pregnancy and cardiovascular ailments, genetic testing of cardiomyopathies, and cardiac evaluation in patients awaiting kidney transplants. [Extracted from the article]

Background: Deploying mobile health vans (MHVs) to service disadvantaged, underserved mountainous hamlets across six districts of Uttarakhand on a “fixed day-fixed location” strategy was an effective initiative in the state in collaboration with Technology Information Forecasting and Assessment Council (TIFAC) and NRHM. Aims and Objectives: The aim of the study was to provide quality diagnostic and curative care through mobile health clinics at select mountainous outreaches of Uttarakhand state. Materials and Methods: A bimonthly mobile health services with fully equipped MHV sponsored by the directorate of science and TIFAC and assessment council and Government of Uttarakhand on a “fixed day, fixed time and fixed place” schedule were provided along pre-designated service locations. Results: A total of 77,688 beneficiaries received services through 902 camps spanning 13 quarters with an estimated 5976 and 89 beneficiaries per quarter per camp; 573 clients received ultrasound, 639 X-ray, 34 ECG, and 3543 other lab procedures. Quarterly demand for services was highest, 19.5% for gastrointestinal disorders, followed by 18.4% for musculoskeletal disorders, 13.8% for genitourinary system disorders, 11.8% for respiratory system disorders, and 8.5% for ENT and ocular disorders. The prevalent morbidity was predominantly acid peptic disease (15.5%), followed by osteoarthritis (13.3%) and low backache and renal stones (7.2% each). Conclusion: Integrating mobile health service delivery component with existing strategies adopted by public health system in primary health care is an operationally feasible and viable option to address ‘inaccessibility at disadvantaged mountainous outreach. [ABSTRACT FROM AUTHOR]

This paper presents a mathematical model of a power controller for a high-frequency induction heating system based on a modified half-bridge series resonant inverter. The output real power is precise over the heating coil, and this real power is processed as a feedback signal that contends a closed-loop topology with a proportional-integral-derivative controller. This technique enables both control of the closed-loop power and determination of the stability of the high-frequency inverter. Unlike the topologies of existing power controllers, the proposed topology enables direct control of the real power of the high-frequency inverter.

Using Gas Tungsten Arc Welding, or TIG Welding, good quality weld can be obtained. In this process, a shielding Gas is used to avoid atmospheric contamination of the molten weld pool. In the present work, bead profile in aluminium workpiece is observed as welded by AC TIG welding under 100% argon gas shield. Effects of variation of arc frequency, current and stand-off distance on bead profile are investigated. In the experiment, the bead-on-plate welding of 14 treatments is performed on Al 1000 series aluminium plates without a filler wire utilizing Central Composite Design system of Response Surface Methodology (RSM). Gas pressure is maintained at 2 kg/cm2 with gas flow rate of 15 lit/min, welding speed of 100 mm/min, electrode diameter of 3 mm and wave balance of -25. From this investigation, it is observed that an increase in welding current increases weld penetration. These are caused by the increase in heat input with the increase in weld current and decrease in torch travel speed. An increase in stand-off distance is also observed to cause a decrease in weld penetration. Analysis of variance (ANOVA) is also performed on the observed results. Regression equations are formed relating the response to the factors (independent variables). Linear relationships are found to be quite significant for both the cases of penetration and weld bead width. Acceptable correlation coefficients (R2) more than 95% are obtained in case of depth of penetration and more than 99% in case of bead width indicating effectiveness of the results observed. [ABSTRACT FROM AUTHOR]

Purpose: As part of the European risk management plan of a 91‐day extended levonorgestrel‐containing combined oral contraceptive (COCLNG), a study was performed to assess its safety. This analysis was conducted to examine delayed pregnancy detection and return to fertility with extended combined oral contraceptives (COC). Methods: We conducted a retrospective cohort study in new users of 91‐day COCLNG or 28‐day COCLNG within a US‐based healthcare claims database from 2006 to 2017. Delayed pregnancy detection during current COCLNG exposure was defined as the time between estimated pregnancy start and first prenatal care encounter. Additionally, the time between estimated pregnancy start and COCLNG discontinuation was measured. To measure return to fertility, pregnancy rates were estimated among females who discontinued treatment. 91‐day COCLNG users were propensity score‐matched to 28‐day COCLNG users. Hazard ratio for pregnancy was calculated using Cox proportional hazards models. Results: The 91‐day and 28‐day COCLNG users had 25 593 and 76 586 treatment episodes, respectively. The median time to pregnancy detection was 64.5 and 61.0 days (p = 0.24) in users of 91‐day COCLNG and 28‐day COCLNG. The median exposure time to treatment after estimated pregnancy start was 54.0 and 38.0 days (p < 0.01). In the fertility analysis, pregnancy rates were 54.82 (95% CI, 50.05–59.93) and 69.30 (95% CI, 64.98–73.82) per 1000 person‐years in extended COCLNG discontinuers and 28‐day COCLNG discontinuers. The adjusted hazard ratio of pregnancy was 0.77 (95% CI, 0.69–0.85). Conclusions: Small differences were observed for pregnancy rates and delayed pregnancy detection between 91‐day extended COCLNG and 28‐day COCLNG, which may be related to the longer days' supply of extended COCLNG. Differences in the fertility analysis may be related to unmeasured residual confounding. [ABSTRACT FROM AUTHOR]

Introduction: SARS-CoV-2 respiratory infection leads to two-layered pathology in time (a) immediate pathology and recovery or fatal ending and (b) long periods of remission followed by unexplained clinical expressions involving one or more systems with various clinical presentations, even leading to loss of lives. Among the common causative factors affecting nearly all organs and systems, oxygen radicals and oxygen-derived species (ROS) should rank conclusively on top. Objective: This clinical report, part of a community screening of unexplained clinical outcomes in post-COVID presentation, carries findings focusing on ROS production and possible ROS-induced damages. Materials and Methods: Flow cytometry was used to quantify the samples' total ROS, superoxide production, and apoptosis quantification. Results: Observations indicate unexplained nearly uniform enhanced ROS production in all these long COVID subjects, although clinical presentations varied from no complaints to the requirement of advanced interventions. Conclusion: Causative factors leading to raised oxygen-derived toxic intermediaries (ROS) in initiating these variable long COVID presentations are ill-understood yet possibly merit mass screenings and possible intense anti-oxidative therapy given that such antioxidant therapy through oral medications led to rapid lowering of ROS production and improvement of clinical presentations. [ABSTRACT FROM AUTHOR]

Time triggered communication provides fault tolerance and determinism in a distributed dependable real time systems. These systems crucially depend on fault tolerant clock synchronization. The article presents simulation of fault tolerant averaging algorithm for clock synchronization and it's modification for improved convergence. We present the simulation results of synchronization algorithm to verify fault tolerance and convergence to a single time base. By modification, we show how a two node system can also be synchronized eliminating the criteria of minimum three nodes. This article also reports a custom time triggered protocol named as deterministic fault tolerant communication protocol particularly suitable for mission critical applications or safety-critical control applications such as in automotive “by-wire” and aerospace systems. The article also presents a different approach for membership service which is based on majority voting and can be used in systems based on time triggered architecture. [ABSTRACT FROM AUTHOR]

Background: Oral Contraceptive use, BP and BMI are strongly associated variables in terms of socio economic conditions. Oral Contraceptives are an important and widely accepted contraceptive modality used throughout the world. Aim & Objective: This study aims to examine the effects of socio-economic factors on Body Mass Index (BMI), Blood pressure (BP) and contraceptive use by reproductive age-group females of Uttarakhand. Settings and Design: This study utilizes nationwide data from the Fourth National Family Health Survey (NFHS-IV). Methods and Material: Information was collected from Indian Institute of Population Sciences (IIPS) Mumbai and 17,300 women of Uttarakhand were considered for this study. Statistical analysis used: For inter age-group comparisons of blood pressure, BMI and socio-demographic indicators, analysis of variance (ANOVA) technique has been used. Results: The variation in mean age at menarche was found to be significant (p< 0.01, ANOVA). The numbers of live births over the women's total lifetime were lower in the younger age groups (p<0.01, ANOVA). Conclusions: The important findings of present study were that the use of contraceptive tended to have increased BMI and elevated blood pressure, even though the magnitude of these was little (equal to 4% and 40% respectively). [ABSTRACT FROM AUTHOR]

Objective: Open cholecystectomy is still widely practised, more so in the developing countries, due to the high cost of laparoscopic cholecystectomy. However, the long traditional postoperative stay (7-8 days) prevents [...]

Oral non-steroidal anti-inflammatory drugs (NSAIDs) are known to be associated with an increased risk of bleeding. The NSAID, flurbiprofen, in the form of 8.75 mg lozenge or oromucosal spray is indicated for the symptomatic relief of sore throat. Despite the low dose as compared to alternative flurbiprofen preparations, concerns have been raised regarding its safety in terms of haemorrhagic events. This systematic review was conducted to identify existing evidence on the risk of haemorrhagic events with flurbiprofen 8.75 mg dose (any formulation), particularly where this may be due to potential interactions with other medicinal products. The systematic review examined studies reporting haemorrhagic events in patients receiving flurbiprofen 8.75 mg dose. Six individual electronic databases were searched up to 28th April 2020. Records were initially screened for relevance followed by further review of potentially eligible studies. Data extraction was performed for eligible studies and risk of bias in studies was assessed. The search strategy identified 1093 individual records. Of these, 1038 records were excluded after initial review; the majority of these records related to flurbiprofen in alternative formulations with alternative doses (e.g., eye drops, skin patches, oral tablets) thus were not considered relevant for further review. The 55 remaining records related to flurbiprofen 8.75 mg dose (any formulation) or flurbiprofen lozenge/oromucosal spray where the dose was not specified. After further review, 52 of these records were not considered eligible. Thus, only three records were included in this systematic review. The three studies reported a total of five haemorrhagic events in patients taking flurbiprofen 8.75 mg lozenge; the corresponding risk in each of the studies was 8.33, 1.98 and 1.96%. Where possible, comparison of flurbiprofen 8.75 mg lozenge to placebo produced risk ratios of 0.96 (95% CI 0.07, 13.25) and 2.00 (95% CI 0.10, 118.0). This systematic review found limited evidence on the risk of haemorrhagic events with flurbiprofen when used at a dose of 8.75 mg. Counts were low across all studies and results comparing flurbiprofen and placebo treatment arms were non-significant. However, scarcity of studies and low certainty of evidence for the outcome of haemorrhagic events limits the conclusions of this systematic review. [ABSTRACT FROM AUTHOR]

Background: Ovaleap® (follitropin alfa), a recombinant human follicle stimulating hormone, is a biosimilar medicinal product to Gonal-f® and is used for ovarian stimulation. The main objective of this study was to assess the safety and effectiveness of Ovaleap® compared to Gonal-f® in one treatment cycle in routine clinical practice. Methods: Safety of Ovaleap® Follitropin alfa in Infertile women undergoing superovulation for Assisted reproductive technologies (SOFIA) was a prospective cohort study conducted in six European countries. Eligible patients were infertile women undergoing superovulation for assisted reproductive technology, who were administered Ovaleap® or Gonal-f® for ovarian stimulation and were naïve to follicle stimulating hormone treatment. The recruitment ratio was 1:1. The primary endpoint was incidence proportion of ovarian hyperstimulation syndrome (OHSS) and the secondary endpoint was OHSS severity (Grades I, II, III). The effect of risk factors or potential confounders on the odds ratio for OHSS incidence as well as treatment effect on OHSS incidence was explored using univariate logistic regression. Pregnancy and live birth rates were also assessed. Results: A total of 408 women who were administered Ovaleap® and 409 women who were administered Gonal-f® were eligible for analysis. The incidence proportion of OHSS was 5.1% (95% CI: 3.4, 7.7) in the Ovaleap® cohort and 3.2% (95% CI: 1.9, 5.4) in the Gonal-f® cohort. This difference in OHSS incidence proportion between the two cohorts was not statistically significant neither before (p = 0.159) nor after univariate adjustment for each potential confounder (p > 0.05). The incidence proportion of OHSS severity grades was similar in the two treatment groups (3.4% versus 2.0% for Grade I, 1.2% versus 1.0% for Grade II, and 0.5% versus 0.2% for Grade III, in the Ovaleap® and Gonal-f® cohorts, respectively), without a significant statistical difference (p = 0.865, for each grade). Among patients who had embryo transfer, clinical pregnancy rates were 33% and 31% and live birth rates were 27% and 26%, in the two cohorts, respectively. Conclusions: Findings from the SOFIA study indicate that the incidence proportions of OHSS and OHSS severity, as well as pregnancy and live birth rates, are similar between Ovaleap® and Gonal-f® treatments and corroborate the safety and effectiveness of Ovaleap® as a biosimilar to Gonal-f®. [ABSTRACT FROM AUTHOR]

As part of the risk management plan in Europe, this study was conducted to characterize drug utilization patterns of Seasonique, a 91 day extended levonorgestrel-containing combined oral contraceptive (COCLNG). A retrospective observational study was conducted in France, Italy and Belgium using electronic medical record databases obtained from general practitioners (GPs) in all participating countries and gynecologists in France from 2015 to 2018. The study population included women receiving ≥1 prescription of 91 day COCLNG during the study period. Prescribing patterns of 91 day COCLNG were examined including: (1) treatment duration; (2) indication; (3) use of combined oral contraceptive (COC) before 91 day COCLNG initiation; and (4) switch from and to combined hormonal contraceptives (CHCs) or other contraceptives. Totals of 235, 220, 207 and 659 women using 91 day COCLNG were identified in French, Italian and Belgian GP, and French gynecologist databases, respectively. Across databases, 46–76% of women were prescribed a single 91 day COCLNG prescription and median treatment duration ranged from 3 to 6 months. The most common indication was contraception (42–81%), followed by menstrual migraines (2–14%). Use of COC during the 6 months prior to 91 day COCLNG initiation was 14% across GP databases, but was lower (8%) in the French gynecologist database. The frequency of switching from 91 day COCLNG to CHCs or other contraceptives was generally low (5–12%), with the highest proportion being among patients of French gynecologists. Findings indicate that 91 day COCLNG was prescribed for relatively short durations and predominantly as indicated for contraception. Most results were comparable across all participating countries. Findings from this drug utilization study in European databases across general practitioners and French gynecologists confirmed that 91 day extended levonorgestrel-containing combined oral contraceptive (COCLNG) was prescribed for relatively short durations (median 3–6 months); predominantly for the intended indication of contraception. Combined oral contraceptive use during the 6 months prior to 91 day COCLNG initiation, and switching from 91 day COCLNG to combined hormonal contraceptives or other contraceptives, were generally low (14% or less). These findings were mostly consistent across participating countries. [ABSTRACT FROM AUTHOR]

Introduction: Although the direct oral anticoagulant rivaroxaban is recommended for stroke prevention in patients with non-valvular atrial fibrillation based on Phase III clinical trials, there is still a need for additional safety data from everyday clinical practice. The ROSE study was initiated to collect further information on the safety and utilisation of rivaroxaban in a broader range of patient groups in routine clinical practice. Methods and results: The ROSE study was conducted in hospitals in England and Wales. Consenting adults with non-valvular atrial fibrillation newly started on rivaroxaban were eligible and followed up for 12 weeks. Data was derived through secondary use of medical records. The primary outcome was major bleeding within gastrointestinal, urogenital and intracranial sites. A total of 4846 patients were enrolled in the study September 2013 to January 2016, 965 of which were treated with rivaroxaban for non-valvular atrial fibrillation. The median age in the rivaroxaban non-valvular atrial fibrillation cohort was 76 years, 53.6% were male. The median HAS-BLED score was 2 and the median CHA2DS2-VASc score was 4. The risk of major bleeding within each of the primary sites of gastrointestinal, urogenital and intracranial during the 12 week observation period was low (0.2%; n = 2). The risk of major bleeding in all sites was 1.0% (n = 10) at a rate of 5.5 events per 100 patient years. Conclusion: In terms of the primary outcome risk of major bleeding within gastrointestinal, urogenital and intracranial sites during the 12 week observation period, the risk estimates in the non-valvular atrial fibrillation rivaroxaban user population were low (<1%), and consistent with risk estimated from clinical trial data and in routine clinical practice. [ABSTRACT FROM AUTHOR]

Summary: Short‐circuit faults are the most commonly occurring faults in an electrical power system. Traditionally, circuit breakers, fuses or similar protective devices are used to safeguard sensitive equipment from these faults by disconnecting the supply. An alternative approach for protection against short‐circuit faults is using fault current limiters (FCL), which suppress the large magnitude currents created by the fault to manageable values. This fault limiting action not only prevents damage to delicate equipment but also aids in providing uninterrupted power supply to the consumers. A promising FCL design is the saturated iron‐core superconducting fault current limiter (SISFCL), which uses the property of its ferromagnetic core to suppress high‐magnitude currents. In this paper, the performance of an open‐core type three‐phase SISFCL is analysed in response to variation of three model parameters. The parametric analysis is performed on the SISFCL under the effects of a symmetric‐type three line to ground (LLLG) fault and an asymmetric‐type single line to ground (SLG) fault. A finite‐element modelling (FEM) approach is used in the design and simulation of the model in ANSYS Maxwell software. Following the parametric analysis, an optimization of the design of the SISFCL is performed using the Quasi‐Newton Gradient Search method, in order to improve its performance against both LLLG and SLG faults. [ABSTRACT FROM AUTHOR]

Introduction: Atorvastatin-80mg/day and Rosuvastatin-40mg/day are the commonest high-dose statin (3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors) regimes for post-PCI (Percutaneous Coronary Interventions) patients to lower (by ≥50%) blood low-density-lipoprotein cholesterol (LDL-C). Dearth of conclusive evidence from developing world, regarding overall safety, tolerability and comparative effectiveness (outcome/safety/tolerability/endothelial inflammation control) of Rosuvastatin over Atorvastatin in high-dose, given its higher cost, called for an overall and comparative assessment among post-PCI patients in a tertiary cardiac-care hospital of Kolkata, India. Methods: A record-based non-concurrent cohort study was conducted involving 942 post-PCI patients, aged 18–75 years, on high-dose statin for three months and followed up for ≥one year. Those on Atorvastatin-80mg (n = 321) and Rosuvastatin-40mg (n = 621) were compared regarding outcome (death/non-fatal myocardial infarction: MI/repeated hospitalization/target-vessel revascularisation/control of LDL and high-sensitivity C-reactive protein: hsCRP), safety (transaminitis/myopathy/myalgia/myositis/rhabdomyolysis), tolerability (gastroesophageal reflux disease: GERD/gastritis) and inflammation control adjusting for socio-demographics, tobacco-use, medications and comorbidities using SAS-9.4. Results: Groups varied minimally regarding distribution of age/gender/tobacco-use/medication/comorbidity/baseline (pre-PCI) LDL and hs-CRP level. During one-year post-PCI follow up, none died. One acute MI and two target vessel revascularizations occurred per group. Repeated hospitalization for angina/stroke was 2.18% in Atorvastatin group vs. 2.90% in Rosuvastatin group. At three-months follow up, GERD/Gastritis (2.18% vs 4.83%), uncontrolled hs-CRP (22.74% vs 31.08%) and overall non-tolerability (4.67% vs. 8.21%) were lower for Atorvastatin group. Multiple logistic regression did show that compared to Atorvastatin-80mg, Rosuvastatin-40mg regime had poorer control of hs-CRP (A3OR = 1.45,p = 0.0202), higher (A3OR = 2.07) adverse effects, poorer safety profile (A3OR = 1.23), higher GERD/Gastritis (A3OR = 1.50) and poorer overall tolerability (A3OR = 1.50). Conclusion: Post-PCI high dose statins were effective, safe and well-tolerated. High dose Rosuvastatin as compared to high dose Atorvastatin were similar in their clinical efficacy. Patients treated with Atrovastatin had significantly lower number of patients with hs-CRP (high-sensitivity C-reactive protein)/C-reactive protein (CRP) level beyond comparable safe limit and relatively better tolerated as opposed to Rosuvastatin-40mg.Thus given the lower price, Atorvastatin 80mg/day appeared to be more cost-effective. A head-to-head cost-effectiveness as well as efficacy trial may be the need of the hour. [ABSTRACT FROM AUTHOR]

A very common kind of fault that appear in an electrical power system is the short-circuit fault, which were traditionally handled by the use of protective devices like fuses or circuit breakers which would disconnect the power supply to protect the components of the network. An alternative to these are fault current limiters (FCL), which are protective devices that limit or suppress the high-magnitude currents created during a short-circuit fault, thereby preventing damage to sensitive equipment and also aid in providing uninterrupted power supply to the consumers. A saturated iron-core superconducting fault current limiter (SISFCL) employs the ferromagnetic property of its core material to automatically suppress high-magnitude currents. In this paper, the performance of an open-core type three-phase SISFCL design is evaluated against three different kinds of short-circuit faults. The analysis is performed using finite element modelling (FEM) in the ANSYS Maxwell software environment. [ABSTRACT FROM AUTHOR]